Search hospitals > Wisconsin > Mukwonago
ProHealth D N Greenwald Center
Claim this profileMukwonago, Wisconsin 53149
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Relapse
Conducts research for Stomach Cancer
154 reported clinical trials
1 medical researcher
Summary
ProHealth D N Greenwald Center is a medical facility located in Mukwonago, Wisconsin. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Relapse, Stomach Cancer and other specialties. ProHealth D N Greenwald Center is involved with conducting 154 clinical trials across 280 conditions. There are 1 research doctors associated with this hospital, such as Timothy Wassenaar, MD.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Clinical Trials running at ProHealth D N Greenwald Center
Skin Cancer
Breast Cancer
Lung Cancer
Bladder Cancer
Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Ovarian Cancer
Stomach Cancer
Throat Cancer
Kidney Cancer
MRI Monitoring vs. Preventive Brain Radiation
for Small Cell Lung Cancer
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Recruiting2 awards Phase 322 criteria
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting2 awards Phase 3
Cetuximab + Pembrolizumab
for Head and Neck Cancer
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.
Recruiting2 awards Phase 316 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at ProHealth D N Greenwald Center?
ProHealth D N Greenwald Center is a medical facility located in Mukwonago, Wisconsin. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Relapse, Stomach Cancer and other specialties. ProHealth D N Greenwald Center is involved with conducting 154 clinical trials across 280 conditions. There are 1 research doctors associated with this hospital, such as Timothy Wassenaar, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.